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Abstract
Human papillomavirus (HPV) is detected in a subset of patients with head and neck squamous cell
carcinoma, most frequently in tumors in the Waldeyer’s ring (palatine tonsil and base of tongue).
Several studies suggest that patients with HPV-positive tumors have better survival with either
concurrent chemoradiation therapy or surgery followed by radiation compared with HPV-negative
patients. However, some possible confounding clinicopathologic variables may challenge the validity
of this statement, for example, some authors used the TNM (tumor, node, metastasis) grouping stage
while others used the primary tumor (T stage), and other studies have demonstrated that tumors
with advanced T stage were less likely to be infected with HPV. A large clinical trial with stratification
of patients according to all known tumor prognostic factors is crucial to solve the question.
Introduction and context
It has been well established that alcohol use or cigarette
smoking or both are the most significant risk factors for
the development of head and neck squamous cell
carcinomas (HNSCCs). However, nearly every head
and neck oncologist has come across patients, most of
them young, with little or no tobacco or alcohol
consumption (up to 20% in some cases) [1].
Sturgis and Cinciripini [2] demonstrated decreasing
incidence rates for tobacco-associated oral, pharyn-
geal, and laryngeal cancers since the mid-1980s, and
these rates trailed the declines in smoking prevalence
by 10-15 years. On the other hand, oropharyngeal
cancer is not demonstrating a similar decline [3].
Shiboski et al. [4] found a dramatic rise in the
incidence rates of oropharyngeal cancer in adults
younger than 45 years of age in the US (2% per year
f o rb a s e - o f - t o n g u ec a n c e ra n d4 %p e ry e a rf o rt o n s i l
cancer). As far back as 1982, the presence of human
papillomavirus (HPV) antigens in 36% of pathologic
specimens of laryngeal cancers was demonstrated [5].
Since then, several hundred papers on this topic have
been published. We made a query on PubMed using
the key words ‘HPV, head and neck cancer’ and found
1410 papers.
Recent advances
HPV genomic DNA was detected in 26% of all HNSCCs
[6], whereas approximately 50% of oropharyngeal
cancers contained the HPV genome [7]. By contrast, in
a multinational study, only 18% of oropharyngeal
tumors were HPV
+ [8], indicating that this proportion
varies with geography and sexual behavior (history of
performing oral sex and oral-anal contact) [9]. Some
studies found that patients who had sexual intercourse at
an early age and more than six oral sexual partners in
their lifetime had a fivefold risk of having HPV in their
tumor compared with patients with no oral sexual
partners [10,11]. Also, a significant racial difference in
HPV positivity was found in a clinical trial of induction
chemotherapy followed by concurrent chemoradiation
therapy between white patients (35%) and black patients
(4%) [12].
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F1000 Medicine ReportsSeveral studies demonstrated an improved prognosis for
patients with HPV
+ tumors versus patients with HPV
−
tumors with (chemo)radiation treatment [7,13,14].
Other studies found the same results in both patients
treated with radiation or surgery and radiation [15-18].
Haraf et al. [19], investigating the correlation between
HPV infection and p53 mutation in HNSCCs, found that
patients with p53 mutations had a history of heavier
smoking in comparison with patients with HPV infec-
tion, who conversely had a more advanced stage at
diagnosis. In a paper from our institution [20], we
analyzed a homogenous group of surgically treated
oropharyngeal cancers with or without postoperative
radiotherapy according to commonly accepted patholo-
gic risk factors. Patients were divided into three groups
according to HPV, TP53 (tumor protein p53), and p16
status. Patients harboring high-risk HPV showed a
significant improvement in terms of survival and
occurrence of relapse and a lower incidence of smok-
ing-related second primary tumors, independently of
tumor stage and delivered treatment (surgery alone or
surgery and postoperative radiotherapy), thus confirm-
ing that HPV
+ tumors represent a distinct disease among
oropharyngeal cancers. In contrast, p53 mutation and
p16 status seemed to lack prognostic significance in the
absence of HPV infection. Similar results are reported by
Weinberger et al. [21].
Begum et al. [22] detected HPV-16 in 22 of 68 (32%)
lymph node metastases in patients with HNSCC and
found that all HPV-16
+ lymph nodes were metastases
from the oropharynx. Goldenberg et al. [23] found a
correlation between patients with cystic lymph node
metastases and the presence of HPV DNA. Almost all of
these patients had a tumor in the palatine or lingual
tonsil.
Implications for clinical practice
The quoted retrospective analyses must be interpreted
with caution because of possible confounding data. For
example, Schwartz et al. [17] analyzed HPV infection and
survival in oral cancers, but 31.5% of their patients had
an oropharyngeal tumor (tonsil and base of the tongue).
Nevertheless, the association between HPV status and
prognosis seems to be indisputable, with a better disease-
specific survival for patients with HPV
+ oropharyngeal
cancers in comparison with HPV
− patients, whereas
disease-specific survival was similar for HPV
+ or HPV
−
patients with nonoropharyngeal cancer [24]. Some
authors even demonstrated a worse prognosis for HPV
+
patients with laryngeal and hypopharyngeal carcinomas
in comparison with HPV
− patients [25]. Hence, the
matter seems to be restricted to oropharyngeal cancer,
and the diagnosis of HPV positivity should enter as a
routine test for these patients. The most clinically useful
test, in situ hybridization, is available in only a few
centers which is unfortunate, even if p16 immunohis-
tochemistry may serve as a reasonable surrogate [7].
Another possible bias in the interpretation of the results
of some studies is due to the staging of the presented
patients, as some authors used the AJCC-UICC (Amer-
ican Joint Cancer Committee/Union Internationale
Contre le Cancer) stage grouping [12,15,18,20,24,26].
It is well known that in stage III there are T1-N1 and
T3-N0 tumors, and in stage IVA there are T1-N2 and T4a-
N0, and these are clearly different tumors. Looking to
those papers reporting T stage, we may realize that
although overall TNM (tumor, node, metastasis) stage
does not differ by HPV status, HPV
+ tumors are more
likely than HPV
− tumors to have a lower T stage [16,27],
whereas advanced T stage is a significant risk factor for
recurrence and death, independently of HPV status [14].
Some historic papers on results of radiation therapy for
oropharyngeal tumors demonstrated that vegetating
tumors (T1-T2) are more curable than infiltrating tumors
(T4) [28,29]. Shonka et al. [30] demonstrated that
patients with p16
+ oropharyngeal tumors are less likely
to have a persistent viable tumor in neck lymph nodes
after (chemo)radiotherapy and hypothesized that a post-
treatment planned neck dissection may perhaps be
avoided in p16
+ patients.
In conclusion, several authors indicate that the impact of
HPV status must be evaluated in prospective clinical
trials and included as a stratification factor to avoid
potential confusion. The current AJCC-UICC staging
system for oropharyngeal cancer needs to be modified in
order to better reflect different prognoses for patients
with HPV
+ or HPV
− tumors and those with vegetating or
infiltrating tumors.
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